What to Expect From Moderna's Next Quarterly Earnings Report
/Moderna%20Inc%20meds-by%20Ascannio%20via%20Shutterstock.jpg)
Valued at $13 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage pharmaceutical company. It focuses on discovering and developing messenger RNA (mRNA)- based therapies and vaccines for the treatment of autoimmune conditions, infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases.
The healthcare major is expected to announce its second-quarter results on Thursday, Aug. 7. Ahead of the event, analysts expect Moderna to deliver a loss of $2.97 per share, 10.8% less than $3.33 per share loss reported in the year-ago quarter. On a positive note, the company has surpassed the Street’s bottom-line estimates in each of the past four quarters.
For the full fiscal 2025, analysts expect the company to report a loss of $9.81 per share, 10.6% more than $8.87 per share loss in 2024. While in fiscal 2026, its losses are expected to reduce by 29.4% year-over-year to $6.93 per share.
MRNA stock has plummeted 72.6% over the past 52 weeks, significantly lagging behind the S&P 500 Index’s ($SPX) 12.1% gains and the Health Care Select Sector SPDR Fund’s (XLV) 8.3% decline during the same time frame.
Moderna's stock soared to an all-time high of $497.49 back in August 2021, driven by increased demand for its COVID-19 vaccines. However, since then, the stock has continued to erode investors’ wealth.
Its stock fell 5.3% following the release of its mixed Q1 2025 results on May 1. The company reported revenue of $108 million, down 35.3% year-over-year, missing the Wall Street expectations of $127 million. The revenue decline was primarily due to a decrease in net product sales, resulting from lower vaccination rates compared to the same period last year. Meanwhile, its bottom line came in at a loss of $2.52 per share, slightly better than Street expectations.
The stock has a consensus “Hold” rating overall. Of the 26 analysts covering the stock, opinions include three “Strong Buys,” 19 “Holds,” one “Moderate Sell,” and three “Strong Sells.” As of writing, the stock is trading notably below its mean price target of $42.86.
On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.